Abbreviations {#nomen0010}
=============

α7nACh

:   α7 nicotinic acetylcholine

ED

:   Embryonic day

GPR

:   G protein-couple receptor

3-HK

:   3-hydroxykynurenine

HPA

:   Hypothalamic-pituitary-adrenal

IL-1β

:   Interleukin 1β

IL-6

:   Interleukin 6

IDO

:   indoleamine 2,3-dioxygenase

KATs

:   Kynurenine aminotransferases

KMO

:   Kynurenine-3-monooxygenase

KP

:   Kynurenine pathway

KYNA

:   kynurenic acid

NMDA

:   N-methyl-D-aspartate

NREM

:   Non-REM

REM

:   Rapid eye movement

SD

:   Sleep deprivation

TDO

:   tryptophan 2,3-dioxygenase

TNF-α

:   tumor necrosis factor-α

QUIN

:   Quinolinic acid

ZT

:   Zeitgeber time

1. Introduction {#sec1}
===============

Insufficient sleep has become a persistent problem in our society. Sleep deprivation (SD) and inadequate sleep duration can lead to cognitive impairments and negatively impact daily function ([@bib6]; [@bib91]). While much research has been done on the effects of sleep loss on adult men and women, inadequate sleep during pregnancy has not been thoroughly studied. Physical and hormonal changes women undergo while pregnant have been shown to disrupt normal sleep patterns, with studies demonstrating an increase in sleep duration during the first trimester, followed by a shortening of sleep time and more disrupted sleep in the subsequent trimesters ([@bib15]; [@bib43]).

While the complete impact of these sleep disruptions on fetal development remains largely undefined, rodent experimental systems have been used to assess the impact of SD during pregnancy on fetal outcomes. Emerging studies have assessed in utero conditions, early postnatal changes, and even long-lasting phenotypic differences in the offspring. Examples include increased ultrasonic vocalizations and low birth weight in pups before weaning ([@bib40]; [@bib81]), increased risk-taking behavior and hyperactivity during adolescence, and impaired memory task performance during adulthood ([@bib102]). Systemically, offspring from sleep deprived pregnant rodents have dysregulated renal, autonomic and metabolic functioning ([@bib48]; [@bib82]). Nevertheless, while a broad range of detrimental phenotypes has been described after maternal SD, little emphasis has been placed on understanding the underlying molecules or mechanistic pathways impacted by sleep loss during pregnancy.

Recent work connects the kynurenine pathway (KP) of tryptophan degradation to the regulation of sleep ([@bib75]) and with increased catabolism towards the neuroactive metabolite kynurenic acid (KYNA) with sleep loss ([@bib7]; [@bib51]; [@bib98], [@bib99]). Tryptophan is elevated in the serum and brain following periods of prolonged wakefulness ([@bib25]; [@bib93]). Most of tryptophan is metabolized by tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO) into kynurenine ([@bib52]). The subsequent downstream metabolite KYNA is of particular interest in the brain where it is specifically astrocyte-derived ([@bib38]), acts as an antagonist at N-methyl-D-aspartate (NMDA) and α7 nicotinic acetylcholine (α7nACh) receptors, and has been shown to modulate neurotransmission with pathologically relevant up or down fluctuations ([@bib77]; [@bib88]).

Presently, we hypothesized that SD would act as a maternal stressor and influence catabolism of the KP thereby elevating KYNA ([@bib65]). Sleep loss can innately be stressful and rodents exposed to periods of SD show increased corticosterone levels, a key glucocorticoid released by the hypothalamic-adrenal-pituitary (HPA) axis, in serum and brain ([@bib7]; [@bib13]; [@bib54]). These alternations are also accompanied by altered cytokine release in the same tissues ([@bib97]; [@bib100]), suggesting an interplay between the stress response and cytokine release with sleep loss. Given that activation of the stress and immune response could induce tryptophan catabolism via the KP ([@bib24]; [@bib34]; [@bib58], [@bib59]; [@bib71]), we hypothesized increased KYNA in the fetus after SD. Elevated fetal KYNA could negatively impact neurodevelopment ([@bib64]), potentially resulting in long-term alterations in KP metabolism and cognitive deficits in adulthood ([@bib7]; [@bib42]; [@bib73], [@bib74]; [@bib80]).

To test our hypothesis, pregnant rat dams were sleep deprived during the last week of gestation for either one session on embryonic day (ED) 18 or three sessions in a row from ED 16 to ED 18. This gestational time frame, late pregnancy, was chosen as it has been extensively shown to be a critical period sensitive to stress, inflammatory stimuli or kynurenine challenge in utero ([@bib22]; [@bib53]; Pocivavsek et al., 2014 ). Maternal, placental and fetal tissues were collected and levels of corticosterone, cytokines and KP metabolites were assessed. Consistent with our previous findings in adult female rats ([@bib7]), pregnant rats showed a significant increase in corticosterone following SD with little effect on KP metabolism in the maternal tissue, including the brain. While levels of KP metabolites were also unchanged in placental tissue, significant increases in interleukin (IL)-1β and IL-6 were found. Importantly, as hypothesized, fetal brain KYNA was increased following a single session of SD. Taken together, our results indicate a relationship between the maternal stress response, placental immune reactivity and increased formation of KYNA in the fetal brain, introducing the KP as a novel molecular pathway influenced by prenatal sleep loss.

2. Methods {#sec2}
==========

2.1. Animals {#sec2.1}
------------

Pregnant, female Wistar rats were obtained from Charles River Laboratories (Frederick, MD) on ED 2. Animals were singly housed in a temperature-controlled facility, fully accredited by the American Association for the Accreditation of Laboratory Animal Care, at the Maryland Psychiatric Research Center. Rats were kept on a 12/12 h light-dark cycle, where lights on corresponded to ZT 0 and lights off to ZT 12, and had ad libitum access to food and water. All experimental protocols were approved by the Institutional Care and Use Committee at the University of Maryland School of Medicine and followed the "Principles of Laboratory Animal Care" (NIH publication No. 86--23, 1996).

2.2. Sleep deprivation, study design and experimental cohorts {#sec2.2}
-------------------------------------------------------------

Rats were sleep deprived with the gentle handling method. Animals remained in their home cages and were presented with objects (i.e. wooden blocks, paper towels, cotton swabs) approximately every 30 min to disrupt sleep. When necessary, animals were gently stimulated with a long cotton tip applicator and cages were shifted to stop the initiation of sleep. Controls remained in their home cages for the duration of the experiment.

The experimental design is shown in [Fig. 1](#fig1){ref-type="fig"}. Upon arriving in our animal facility, pregnant dams were randomly assigned to the various experimental groups. The samples were processed randomly and the experimenter was blind to group assignment during the biochemical analysis. SD was performed for 5 h from ZT 0 to ZT 5 for one session on ED 18 or for three consecutive daily sessions on ED 16, ED 17, and ED 18. The experimental cohorts of dams included i) control, 0 h after SD, ED 18 (N = 6), ii) SD: 1 session, 0 h after SD, ED 18 (N = 5), iii) SD: 3 sessions, 0 h after SD, ED 18 (N = 3), iv) control, 24 h after SD, ED 19 (N = 4), v) SD: 1 session, 24 h after SD, ED 19 (N = 4), and vi) SD: 3 sessions, 24 h after SD, ED 19 (N = 3). A maximum of 10 fetuses and corresponding placenta were dissected from each dam. Fetal blood was pooled among subjects from a single litter. Tissues from both sexes were used without regard to sex.Fig. 1Schematic representation of sleep deprivation (SD) experimental design. Pregnant rat dams were sleep deprived for 5 h from Zeitgeber time (ZT) 0 to ZT 5 for either 1 session on embryonic day (ED) 18 or 3 consecutive daily sessions on ED 16, ED 17, and ED 18. Maternal blood and brain, placenta, and fetal blood and brain were collected.Fig. 1

2.3. Tryptophan, kynurenine, and KYNA biochemical analysis {#sec2.3}
----------------------------------------------------------

Animals were euthanized by CO~2~ asphyxiation at ZT 5 on ED 18 or ED 19. Maternal and fetal blood was collected in tubes containing K~3~-EDTA (0.15%). Brains and placenta were promptly removed and snap-frozen on dry ice. To separate plasma from blood cells, blood was centrifuged (300×*g*, 10 min). The supernatant was removed and stored at −80 °C along with the maternal and fetal brains and placentas. On the day of the assays, fetal brains were weighed and sonicated (1:10 w/v) in ultrapure water for determination of KYNA. Placenta samples were weighed and sonicated (1:10 w/v) in ultrapure water, then further diluted to 1:50 and 1:200 to determine kynurenine and KYNA, respectively. Maternal and fetal plasma was thawed and diluted in ultrapure water to quantify tryptophan (1:100), kynurenine (1:2) and KYNA (1:10). One-hundred μl of sample was acidified with 25 μl of 6% perchloric acid for plasma or 25% perchloric acid for tissue. Samples were centrifuged (12,000×*g*, 10 min) and 20 μl of supernatant was subjected to high-performance liquid chromatography (HPLC). Tryptophan, kynurenine and KYNA were isocratically eluted from a Reprosil-Pur C18 column (4 × 150 mm; Dr. MaischGmbh, Ammerbuch, Germany), using mobile phase containing 50 mM sodium acetate and 5% acetonitrile (pH adjusted to 6.2 using glacial acetic acid) at a flow rate of 0.5 mL/min, and detected with 500 mM zinc acetate delivered after the column at a flow rate of 0.1 mL/min. Tryptophan (excitation 285 nm, emission 365 nm), kynurenine (excitation 365 nm, emission 480 nm) and KYNA (excitation 344 nm, emission 398 nm) were detected fluorometrically (Waters Alliance, 2475 fluorescence detector) in the eluate at a retention time of 11 min, 6 min and 11 min respectively.

2.4. Corticosterone measurement {#sec2.4}
-------------------------------

Maternal and fetal plasma corticosterone levels were determined using a radioimmunoassay (MP Biomedicals, Solon, OH, USA). The sensitivity threshold for this assay was 5 ng/mL. Inter- and intra-assay coefficients of variance were less than 10%. All samples were run in duplicate, with 5 μl of sample used in each tube.

2.5. Cytokine quantification {#sec2.5}
----------------------------

As previously described ([@bib26]), placenta and fetal brain tissues were homogenized in RIPA buffer containing protease inhibitors cocktail (Life Technologies, CA, USA). Samples were centrifuged for 15 min at 15,000 rpm and 4 °C, and supernatants were collected. Protein samples from placenta and fetal brain tissues were tested for proinflammatory cytokines IL-1 β, IL-6 and tumor necrosis factor-α (TNF-α) using ELISA duoset kits (R&D Systems, MN, US) following manufacturer instructions.

2.6. Data handling and statistical analysis {#sec2.6}
-------------------------------------------

Each maternal sample was an independent biological data point. To minimize the contribution of individual litters, placental and fetal samples were handled such that randomized (2--5) samples from each litter were analyzed and considered as one subject in all biochemical experiments. Insufficient amount of fetal plasma was collected from two litters of 1 session, 0 h after SD, thus fetal corticosterone was analyzed in only 3 of these litters. Fetal brain TNFα were below the limit of detection in many cases, resulting in exclusion from analysis. All data are expressed as the mean ± SEM. Non-parametric two-way analyses of variance (Aligned Ranks Transformation ANOVA, or ART ANOVA) were performed to assess the main effects and interaction of SD and recovery. When appropriate, significant main effects were followed by a Bonferroni post hoc test. Spearman correlational analysis was performed to examine relationships between fetal brain KYNA, placental cytokines, and plasma corticosterone levels. Analysis was performed in R (version 3.6.1) using the *ARTool* and *emmeans* packages and a P value of \<0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Increase in maternal, but not fetal, corticosterone after sleep deprivation {#sec3.1}
--------------------------------------------------------------------------------

To determine the impact of SD on the stress response, corticosterone was measured in maternal and fetal plasma. Maternal plasma corticosterone was significantly impacted by sleep condition (F~2,19~ = 7.1, P \< 0.01), recovery time (F~1,19~ = 10.7, P \< 0.01) as well as a sleep condition X recovery time interaction (F~2,19~ = 5.1, P \< 0.05) ([Fig. 2](#fig2){ref-type="fig"}A). In the maternal plasma, corticosterone was increased by 8-fold immediately after one session (P \< 0.001), by 6- fold after three sessions (P \< 0.05) of SD, and returned to baseline levels after 24 h of recovery from SD. While fetal plasma corticosterone levels were not impacted by SD (F~2,17~ = 0.6, P = 0.58), a significant effect of recovery time (F~1,17~ = 22.9, P \< 0.001) was observed, with a trend toward a meaningful sleep condition X recovery time interaction (F~2,17~ = 3.3, P = 0.06) ([Fig. 2](#fig2){ref-type="fig"}B). Of note, fetal plasma corticosterone levels were significantly higher on ED 19 compared to ED 18.Fig. 2Increase in maternal, but not fetal, corticosterone with sleep deprivation (SD). Pregnant rat dams were sleep deprived for 5 h from ZT 0 to ZT 5 for either 1 session on ED 18 or 3 consecutive daily sessions on ED 16, ED 17, and ED 18. Corticosterone levels in (A) maternal and (B) fetal plasma were assessed immediately after SD (0 h after SD), or after recovery (24 h after SD). All data are mean ± SEM. \*P \< 0.05, \*\*\*P \< 0.001 versus control. \$P \< 0.05, \$\$P \< 0.01 versus corresponding 0 h group. N = 3--6 per group.Fig. 2

3.2. Impact of sleep deprivation on KP metabolites in maternal, fetal and placental tissue {#sec3.2}
------------------------------------------------------------------------------------------

Maternal brain KYNA levels were not significantly changed in response to SD (sleep condition: F~2,19~ = 0.4, P = 0.65; recovery time: F~1,19~ = 0.2, P = 0.64; sleep condition X recovery time: F~2,19~ = 0.2, P = 0.86) ([Fig. 3](#fig3){ref-type="fig"}A). Interestingly, fetal brain KYNA was significantly impacted by sleep condition (F~2,19~ = 8.2, P \< 0.01), but not recovery time (F~1,19~ = 3.2, P = 0.09) and there was no significant sleep condition X recovery time interaction (F~2,19~ = 1.6, P = 0.22) ([Fig. 3](#fig3){ref-type="fig"}B). Post hoc analysis indicated that immediately following one session of SD, fetal brain KYNA was significantly elevated by 2.1-fold compared to controls (P \< 0.001) and this change persisted on ED 19 (P \< 0.05).Fig. 3Increase in fetal, but not maternal, brain kynurenic acid (KYNA) with sleep deprivation (SD). Pregnant rat dams were sleep deprived for 5 h from ZT 0 to ZT 5 for either 1 session on ED 18 or 3 consecutive daily sessions on ED 16, ED 17, and ED 18. KYNA levels in (A) maternal and (B) fetal brain were assessed immediately after SD (0 h after SD), or after recovery (24 h after SD). All data are mean ± SEM. \*P \< 0.05, \*\*\*P \< 0.001 versus corresponding control. \#P \< 0.05 versus 0 h 1 session SD. N = 3--6 per group.Fig. 3

To understand the association of increased fetal brain KYNA, tryptophan and KP metabolites in the maternal plasma were assessed. Tryptophan levels in maternal plasma were significantly affected by sleep condition (F~2,19~ = 4.5, P \< 0.05), but not recovery time (F~1,19~ = 0.23, P = 0.63) and there was a slight trend towards an interaction between sleep condition X recovery time (F~2,19~ = 3.0, P = 0.07) ([Fig. 4](#fig4){ref-type="fig"}A). Per post hoc assessment, we found that maternal plasma tryptophan was significantly elevated after one session of SD (P \< 0.05) without recovery and also after one session or three sessions of SD followed by 24 h of recovery when compared to respective controls (P \< 0.05). Maternal plasma kynurenine (sleep condition: F~2,19~ = 3.2, P = 0.06; recovery time: F~1,19~ = 0.2, P = 0.66; sleep condition X recovery time: F~2,19~ = 1.1, P = 0.36) ([Fig. 4](#fig4){ref-type="fig"}B) and KYNA (sleep condition: F~2,19~ = 2.0, P = 0.16; recovery time: F~1,19~ = 0.23, P = 0.64; sleep condition X recovery time: F~2,19~ = 0.12, P = 0.89) ([Fig. 4](#fig4){ref-type="fig"}C) were unchanged with SD. Similarly, placental KP metabolite levels were unaffected by SD. Neither kynurenine (sleep condition: F~2,19~ = 0.2, P = 0.79; recovery time: F~1,19~ = 0.2, P = 0.63; sleep condition X recovery time: F~2,19~ = 0.1, P = 0.90) ([Fig. 5](#fig5){ref-type="fig"}A) nor KYNA (sleep condition: F~2,19~ = 2.6, P = 0.10; recovery time: F~1,19~ = 1.8, P = 0.19; sleep condition X recovery time: F~2,19~ = 1.1, P = 0.37) ([Fig. 5](#fig5){ref-type="fig"}B) levels in the placental tissue were altered following deprivation and/or recovery.Fig. 4Minor changes in maternal plasma tryptophan after sleep deprivation (SD) and recovery. Pregnant rat dams were sleep deprived for 5 h from ZT 0 to ZT 5 for either 1 session on ED 18 or 3 consecutive daily sessions on ED 16, ED 17, and ED 18. Levels of (A) tryptophan, (B) kynurenine and (C) kynurenic acid (KYNA) in the maternal plasma were assessed immediately after SD (0 h after SD), or after recovery (24 h after SD). All data are mean ± SEM. \*P \< 0.05 versus corresponding control. N = 3--6 per group.Fig. 4Fig. 5No change in placenta kynurenine pathway (KP) metabolites following sleep deprivation (SD). Pregnant rat dams were sleep deprived for 5 h from ZT 0 to ZT 5 for either 1 session on ED 18 or 3 consecutive daily sessions on ED 16, ED 17, and ED 18. (A) Kynurenine and (B) KYNA were determined in placental tissues immediately after SD (0 h after SD), or after recovery (24 h after SD). All data are mean ± SEM. N = 3--6 per group.Fig. 5

3.3. Sleep deprivation elevates placental and fetal brain cytokines {#sec3.3}
-------------------------------------------------------------------

As KP metabolism can be initiated by elevated proinflammatory cytokines ([@bib33]), we measured levels of IL-1β, IL-6 and TNFα, in placental and fetal brain tissues. Placental IL-1β levels were impacted by sleep condition (F~2,16~ = 5.0, P \< 0.05) and recovery time (F~1,16~ = 4.9, P \< 0.05), but no interaction was observed between the two factors (F~2,16~ = 1.2, P = 0.33) ([Fig. 6](#fig6){ref-type="fig"}A). One session of SD was sufficient to elevate placental IL-1β by 3-fold compared to controls (P \< 0.05), and then levels of the cytokine returned after recovery. Of note, three sessions of SD did not impact IL-1β levels. Placental IL-6 levels were significantly impacted by an interaction in sleep condition X recovery time (F~2,15~ = 7.7, P \< 0.01) and sleep condition (F~2,15~ = 7.3, P \< 0.01), but not recovery time (F~1,15~ = 3.8, P = 0.07) ([Fig. 6](#fig6){ref-type="fig"}B) alone. Placental IL-6 levels were also elevated by 3-fold after one session of SD (P \< 0.05), but actually dipped significantly below baseline with three session of SD (P \< 0.05) and after 24 of recovery (P \< 0.05). Placental TNFα analysis revealed no significant sleep condition X recovery time interaction (F~2,16~ = 1.3, P = 0.29), and no individual main effect of sleep condition (F~2,16~ = 1.0, P = 0.41) or recovery time (F~1,16~ = 0.7, P = 0.43) ([Fig. 6](#fig6){ref-type="fig"}C).Fig. 6Sleep deprivation (SD) elevates proinflammatory cytokines in placental tissues. Pregnant rat dams were sleep deprived for 5 h from ZT 0 to ZT 5 for either 1 session on ED 18 or 3 consecutive daily sessions on ED 16, ED 17, and ED 18. (A) IL-1β, (B) IL-6 and (C) TNFα in the placenta immediately after SD (0 h after SD), or after recovery (24 h after SD). All data are mean ± SEM. \*P \< 0.05 versus corresponding control. \$P \< 0.05 versus corresponding 0 h group. N = 3--6 per group.Fig. 6

Assessment of fetal brain cytokines showed that levels of IL-1β were significantly affected by a sleep condition X recovery time interaction (F~2,16~ = 6.5, P \< 0.01), but no main effect of sleep condition (F~2,16~ = 1.9, P = 0.18) or recovery time (F~1,16~ = 3.3, P = 0.09) ([Fig. 7](#fig7){ref-type="fig"}A). Consistent with the placental results, fetal brain IL-1β levels were elevated by almost 2-fold after one session of SD (P \< 0.05) and returned to baseline following 24 h of recovery. Fetal brain IL-6 levels were also significantly affected by an interaction between sleep condition X recovery time (F~2,16~ = 5.0, P \< 0.05), however sleep condition (F~2,16~ = 2.0, P = 0.17) and recovery time (F~1,16~ = 1.6, P = 0.23) alone did not have a significant effect on fetal brain IL-6 levels ([Fig. 7](#fig7){ref-type="fig"}B). Levels of TNFα were measured in fetal brain samples but were undetectable in many cases (data not shown).Fig. 7One session of sleep deprivation (SD) elevates proinflammatory cytokines in the fetal brain. Pregnant rat dams were sleep deprived for 5 h from ZT 0 to ZT 5 for either 1 session on ED 18 or 3 consecutive daily sessions on ED 16, ED 17, and ED 18. (A) IL-1β and (B) IL-6 in the fetal brain immediately after SD (0 h after SD), or after recovery (24 h after SD). All data are mean ± SEM. \*P \< 0.05 versus control. N = 3--6 per group.Fig. 7

3.4. Correlational analysis {#sec3.4}
---------------------------

Given the findings described presently, we sought to explore possible relationships between fetal brain KYNA, placental cytokines, and plasma corticosterone levels. A positive correlation was observed between maternal corticosterone and fetal brain KYNA (r = 0.50, P \< 0.05) and we also observed a positive correlation between maternal corticosterone and placental IL-1β (r = 0.46, P \< 0.05). Importantly no relationship was observed between fetal brain KYNA and fetal corticosterone (r = 0.01, P = 0.95). Taken together, these data highlight a relationship between maternal stress reactivity, placental immune response and fetal KP metabolism.

3.5. Data availability {#sec3.5}
----------------------

The data generated in the present study are available from the corresponding author upon reasonable request.

4. Discussion {#sec4}
=============

Our study sought to determine the impact of maternal SD on HPA axis regulation, inflammatory response and KP metabolism. Despite no indication of KP dysfunction in maternal tissues, a significant increase in fetal brain KYNA was observed following a single day of SD. This was accompanied by an increase in maternal corticosterone and elevated proinflammatory cytokine levels, namely IL-1β and IL-6, in placenta and fetal brain. Taken together, these results support the notion that in utero stress and immune reactivity may drive changes in fetal brain KYNA and inflammation. Our findings implicate KYNA as a novel molecule by which maternal sleep loss during pregnancy could impact fetal neurodevelopment.

In rodents and humans, healthy fetal brain development is critically linked to endocrine and immunological homeostasis between the mother and fetus. The significance of the placenta\'s fundamental role in modulating pathophysiological responses to maternal insults is well established ([@bib14]; [@bib44]; [@bib67]). Fetal exposure to maternal glucocorticoids or placental proinflammatory cytokines can exert detrimental effects on brain development ([@bib9]; [@bib11]; [@bib28]; [@bib61]; [@bib66]; [@bib87]). In relation to the KP, a recent study demonstrated that acute restraint stress transiently increased fetal brain KYNA ([@bib65]). Our study bridges several of these concepts by demonstrating for the first time that increased maternal corticosterone due to sleep loss can adversely impact the endocrine and immunological homeostasis in utero and thereby significantly alter fetal brain KYNA.

Herein, SD in pregnant rats was induced by the gentle handling method, which we have previously shown to effectively eliminate rapid eye movement (REM) sleep and substantially (\>95%) reduce non-REM (NREM) sleep ([@bib7]). In line with our findings of increased circulating maternal, but not fetal, levels of corticosterone, other studies have shown elevated corticosterone levels following sleep loss ([@bib7]; [@bib17]). The sleep loss-induced elevation in circulating corticosterone can subsequently activate the enzyme TDO, which converts tryptophan to kynurenine ([@bib34]; [@bib68]). Stress-induced increases in TDO have been shown to elevate kynurenine and downstream metabolites in the brain and periphery ([@bib58], [@bib59]; [@bib71]). IDO, which also converts tryptophan to kynurenine, is alternatively induced by immunological activation and elevated cytokines ([@bib24]; [@bib35]). While we presently demonstrate that maternal SD elevated plasma corticosterone and tryptophan, this elevation did not result in higher maternal or placenta KP metabolism. Instead, we find that maternal corticosterone correlated highly with placental cytokine levels, as in other models of prenatal stress ([@bib14]; [@bib41]). To our knowledge, our findings are the first to demonstrate a within subject correlation among these factors in a prenatal sleep manipulation study.

The observed increase in proinflammatory cytokine levels in the placenta following SD may indicate a mechanism by which maternal physiological alterations in response to stress could directly or indirectly affect the fetus. Ex vivo placental perfusions of full-term placentas have demonstrated that cytokines are not transferred across the placenta ([@bib1]), but it is able to produce and release cytokines independently ([@bib12]) and their release can be increased by external factors such as stress or infection ([@bib3]). Such elevations in proinflammatory cytokines are also associated with placental damage ([@bib89]) and intrauterine TNF-α and IL-1β in late pregnancy have also been shown to stimulate preterm labor ([@bib86]), identified as a risk factor for the development of cognitive dysfunction and altered neurodevelopmental outcomes ([@bib60]; [@bib86]). Additionally, fetal brain inflammation may detrimentally impact neurodevelopment, such as the establishment of dendritic processes and the growth of neurons ([@bib16]) as well as cognitive functions later in life ([@bib90]). As observed in our present study, increased fetal brain cytokines may directly stimulate IDO activity ([@bib24]; [@bib35]), leading to the observed overproduction of KYNA.

The implications of sleep loss during pregnancy are multifaceted, but have been poorly investigated. Sleep loss during embryogenesis is a risk factor for pregnancy loss ([@bib17]), poor fetal growth and preterm delivery ([@bib20]; [@bib69]; [@bib70]). Lasting negative impacts of SD during pregnancy, investigated in the developing offspring, include greater amounts of active sleep and less quiet sleep compared to controls, indicative of immature brain development ([@bib4]), and increased ultrasonic vocalizations ([@bib40]), indicative of higher sensitivity to maternal separation. As pre-adolescents, offspring display increased risk-taking behavior ([@bib40]; [@bib81]) and deficits in hippocampal-dependent learning and memory ([@bib101], [@bib102]). Pre-adolescent pups also show decreased hippocampal neurogenesis and increased neuroinflammation ([@bib101], [@bib102]). Adult offspring of SD mothers present with many of the same behavioral changes, increased anxiety and impaired cognitive performance, indicating that these changes are long-lasting ([@bib72]). Additionally, adult offspring have higher body weights, increased visceral adipose tissue and display insulin resistance, indicating metabolic changes following maternal SD in addition to persistent cognitive deficits ([@bib48]; [@bib94]). While there have been few studies attempting to elucidate the mechanism behind these changes, our findings introduce elevated KYNA as a molecular underpinning.

Elevations in fetal brain KYNA disrupt normal neurodevelopment ([@bib64]). Adult offspring from rat dams fed a kynurenine-laced diet, resulting in higher fetal brain KYNA levels, display cognitive deficits, morphological, and biochemical alterations ([@bib42]; [@bib73], [@bib74]; [@bib80], [@bib76]). Elevations in fetal brain KYNA by a pharmacological inhibitor of kynurenine-3-monooxygenase (KMO), the enzyme responsible for metabolizing kynurenine into 3-hydroxykynurenine (3-HK), resulted in functional consequences on synaptic transmission in adulthood ([@bib29], [@bib30], [@bib31]; [@bib47]). These studies together support the notion that the KP plays a role in neurodevelopment and altering levels of fetal brain KYNA, as we induced with maternal SD, may also lead to long-lasting functional changes, to be explored in the future.

Moreover, the KP has been found to play many roles during pregnancy ([@bib5]; [@bib46]), including supporting fetal implantation and neuronal protection, which are most likely due to an interplay between maternal, placental and fetal metabolite levels. The placenta can metabolize tryptophan ([@bib55]) and thus act as a source to elevate KP metabolites, namely kynurenine, in the fetus without elevations in maternal plasma. Since the placenta is highly vascularized ([@bib103]), sources of tryptophan, kynurenine, and KYNA within the placenta could be partly due to residual blood, as we previously investigated by perfusing pregnant dams ([@bib36]). A limitation presently is that we were unable to measure placental tryptophan after SD in utero. However, we were able to determine no alterations in placental kynurenine and KYNA after SD. Considering the impact of placental sources on the fetal brain KP metabolites, we recognize that tryptophan and kynurenine could readily cross the placental barrier, but even vascular components of KYNA within the placenta are not likely to contribute to KYNA levels in the fetus as this metabolite does not readily cross the placental barrier ([@bib36]; [@bib63]). While the fetal tissues themselves can take maternal or fetal derived kynurenine and de novo synthesize KYNA, via transamination by kynurenine aminotransferases (KATs) ([@bib36]; [@bib63]), the exact source of fetal derived brain KYNA remains elusive in vivo since the fetal liver also has a great ability to metabolize kynurenine ([@bib8]; [@bib18]; [@bib19]; [@bib62]; [@bib64]). Recent evidence supports the notion that the fetal rodent brain has the necessary enzymatic machinery to synthesize KYNA ([@bib63]), and this source of KYNA is hypothesized to be responsible for its neurodevelopmental impacts ([@bib64]).

Mechanistically, we speculate that the impact of fetal brain KYNA on neurodevelopment may be via its antagonism of NMDA and α7nACh receptor function. Both receptor classes have been implicated in regulating neurodevelopment, including the development and morphology of dendritic spines, maintaining the stability of synapses, survival of neurons, and modulation of excitatory-inhibitory circuits during development ([@bib2]; [@bib45]; [@bib56], [@bib57]; [@bib83]; [@bib95]). However, we also consider that KYNA has been found to activate signaling receptors, including G protein-couple receptor (GPR) 35 and the aryl hydrocarbon, that are functional in both the brain and periphery ([@bib77]). Additionally, while the focus of this study was on KYNA formation in fetal tissue, it is important to consider the alternative branch of the KP that generates 3-HK, 3-hydroxyanthranilic acid and quinolinic acid (QUIN), which may induce generation of free radicals and downstream neurotoxic effects ([@bib32]; [@bib39]; [@bib88]). From our previous SD experiments in adult rats, we determined that acute loss of sleep does not alter 3-HK formation in the adult rat brain ([@bib7]). Given that SD triggers oxidative processes ([@bib17]; [@bib23]; [@bib27]; [@bib37]; [@bib84]) it remains to be seen if maternal SD could in part also lead to an increased production of KP metabolites through both enzymatic and oxidative mechanisms ([@bib10]; [@bib63]).

Assessing our findings after one session of SD between animals that were euthanized immediately or allowed 24 h of recovery, we determined that some of the striking effects were normalized with recovery sleep. This is most likely due to the phenomenon of rebound sleep, where animals exposed to acute SD exhibit increases in sleep duration during the recovery period ([@bib85]; [@bib92]). We speculate that this increase in sleep reinstates homeostatic levels of cytokines and corticosterone. Unexpectedly, though, we observed very few changes following three sessions of SD. It remains to be seen if this may be due to compensatory mechanisms that, after multiple exposures to SD, help to initiate an allostatic response ([@bib49]; [@bib96]).

Our present findings place new attention on the KP as a possible mechanism by which maternal stress, in the form of sleep disturbances, can negatively impact fetal neurodevelopment. It is also enticing to speculate that a rise in prenatal KP metabolism described here may be a physiologically protective response in utero. This could be considered the fetal brain\'s attempt to protect against excitotoxic damage during development ([@bib19]). The exact process by which maternal glucocorticoids and placental inflammation regulate KP metabolism has yet to be elucidated, including further investigation into the activity of KP enzymes. Future studies investigating the relationship between the maternal-placental-fetal interplay, will provide value in understanding the impacts of prenatal sleep loss on KYNA formation and defining a causal relationship on long-term behavioral outcomes. As we have demonstrated in adult rodents that acute sleep loss differentially impacts brain KYNA levels ([@bib7]), future prenatal studies will also assess the impact of biological sex of the developing embryos. Of note, alterations in KYNA are found in several psychiatric and neurological conditions that are plagued with cognitive dysfunction and sleep abnormalities, highlighting the translational implications of our studies ([@bib21]; [@bib78]; [@bib88]). Leading hypotheses suggest that cognitive impairments and sleep disturbances are interlinked, thus it will be critical to further define the mechanistic contribution of KYNA, and potential therapeutic value of reducing its synthesis via KAT II inhibition ([@bib50]; [@bib76]), as a connection in mediating these relationships in future studies.
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